Abstract:

BACKGROUND: The stent thrombosis has a direct impact on the immediate and long-term outcomes following drug eluting stents implantation.
OBJECTIVE: To evaluate the effects of different dual antiplatelet therapies periods on the incidence of cardiovascular adverse events in patients with coronary heart disease treated by Firebird stents
METHODS: A total of 1 107 consecutive patients with coronary artery disease who received Firebird stent implantation were selected. These patients were divided into three groups based on the time of applying asprin and clopidogrel. Major adverse cardiac events (MACE), drug adverse effect and host response to materials were recorded.
RESULTS AND CONCLUSION: 1 059 cases with 1 431 stents were followed up for 7-59 months, and clinical follow-up rate was 95.7%. Rate of MACE occurrence in the group of applying asprin and clopidogrel over 6 months (4.4%) were much lower than other groups (8.9% and 7.7%), there was significant difference among these groups (P < 0.05). Rate of non-fatal myocardial infarction, heart fail, target vessel revascularization and bleeding occurrence in the group of applying asprin and clopidogrel over 6 months were much lower than other groups, there was significant difference among these groups (P < 0.05 or < 0.01). There was no host response to materials in the three groups. The clinical follow-ups showed that the group of applying asprin and clopidogrel until 12 months has a definite clinical efficacy in the patients with coronary artery disease who received Firebird stent implantation, which could reduce the occurrence of MACEs.